Literature DB >> 18095921

Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.

Mellar P Davis1.   

Abstract

BACKGROUND: Nabilone has been approved to treat chemotherapy-induced nausea and vomiting. Recent studies have explored cannabinoids in pain management.
OBJECTIVES: To review the evidence for the use of cannabinoids in general and nabilone in particular; i) in managing chemotherapy-induced nausea and vomiting; and ii) in treating pain.
METHOD: A systematic review of published English literature used the terms: cancer, cannabinoid, nabilone, nausea, pain, tetrahydrocannabinol and vomiting as search terms. Reviews, meta-analyses and treatment trials were reviewed. RESULTS/
CONCLUSIONS: Nabilone is superior to placebo, domperidone and prochlorperazine but not metoclopramide or chlorpromazine. Cannabinoids do not add to benefits of 5-HT(3) receptor antagonists. Side effects are greater for nabilone than for prochlorperazine, in most studies patients prefered nabilone over prochlorperazine. Nabilone is ineffective in acute pain but benefits in neuropathic pain and central hypersensitization. Recent guidelines place nabilone as a second to fourth line drug for neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18095921     DOI: 10.1517/13543784.17.1.85

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  21 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo.

Authors:  Jason R Clapper; Federica Vacondio; Alvin R King; Andrea Duranti; Andrea Tontini; Claudia Silva; Silvano Sanchini; Giorgio Tarzia; Marco Mor; Daniele Piomelli
Journal:  ChemMedChem       Date:  2009-09       Impact factor: 3.466

Review 4.  Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Authors:  Srikrishnan Mallipeddi; David R Janero; Nikolai Zvonok; Alexandros Makriyannis
Journal:  Biochem Pharmacol       Date:  2016-11-24       Impact factor: 5.858

Review 5.  Medicinal cannabinoids in palliative care.

Authors:  Meera Agar
Journal:  Br J Clin Pharmacol       Date:  2018-08-12       Impact factor: 4.335

Review 6.  Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.

Authors:  S Tafelski; W Häuser; M Schäfer
Journal:  Schmerz       Date:  2016-02       Impact factor: 1.107

Review 7.  The endocannabinoid system and cancer: therapeutic implication.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

8.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

Review 9.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec

Review 10.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.